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Background: We previously calculated a risk factor summation score that success-
fully predicted survival after insertion of a left ventricular assist device. We sought
to validate our previous score by using a single center’s clinical experience and to
determine emerging risk factors for mortality after device insertion.
Methods: The clinical records of 130 consecutive patients who received the Heart-
Mate VE left ventricular assist device (Thoratec Corp, Pleasanton, Calif) at our
institution between June 1996 and March 2001 as a bridge to transplantation were
reviewed. Univariate and multivariable analyses were performed to determine the
predictors of operative mortality after device insertion. Using the relative risks for
each identified variable, we devised a new risk factor summation score. The new and
old scores were then compared by using linear regression analyses to determine
whether the revised score improved statistical accuracy.
Results: Overall operative mortality was 25% (n  33). The old score successfully
predicted operative mortality in the current patient population (operative mortality
of 38% for score 5 vs 13% for score 5). However, the revised score improved
risk discrimination (operative mortality of 46% for a score 5 vs 12% for a score
 to 5). Statistical accuracy was comparable between scores, but the relationship
between observed and predicted outcomes was improved with the revised score.
Conclusions: The changing demographic profile and management of patients pre-
senting for mechanical circulatory support has led to a change in the predictors of
mortality after device insertion. Periodic remodeling and recalibration of risk
indices helps to accurately predict outcomes in high-risk patient groups and iden-
tifies emerging risk factors for mortality.
The successful use of mechanical circulatory assistance for the man-agement of end-stage heart disease has resulted in the widespreaduse of a variety of devices approved by the Food and Drug Admin-istration as bridges to cardiac transplantation.1-3 For the 2 mostcommon long-term implantable left ventricular assist devices(LVADs), the vented electric HeartMate (Thoratec Corp, Pleasanton,
Calif) and the Novacor (WorldHeart Corp, Ottawa, Ontario, Canada), survival to
transplantation is greater than 70%.2-4
We have previously reported a preoperative screening scale that predicts oper-
ative mortality in patients receiving the 1000IP or 1205VE HeartMate LVAD.5 In
developing this scale, we reviewed 56 consecutive patients who received a device
either at our institution or at The Cleveland Clinic Foundation. All patients met the
hemodynamic criteria for LVAD insertion proposed by Norman and colleagues6: a
cardiac index of less than 2.0 L  min1  m2 with a left atrial or pulmonary
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capillary wedge pressure of greater than 20 mm Hg. A
10-point scale was developed by using 5 factors found to be
statistically significant by means of univariate analysis (Ta-
ble 1). Each factor was weighted according to its relative
risk, and a summation score of greater than 5 was found to
be associated with a prohibitive risk of death (67% opera-
tive mortality).
In 1999, we published the results of an LVAD bridge-
to-transplant network to manage patients with postcar-
diotomy shock.7 In this high-risk subgroup of patients, we
reported a survival to hospital discharge of 66% compared
with a reported survival of less than 20% in patients sup-
ported with triple-inotropic therapy and intra-aortic balloon
pump counterpulsation.8 Since the publication of that report,
we have noticed, in our institution, a substantial increase in
the proportion of patients presenting for LVAD insertion
with a temporary device in situ (bridge-to-bridge support).
These patients have often undergone 2 previous sternoto-
mies with cardiopulmonary bypass and present for a third
bypass run in a span of less than 48 hours for insertion of a
long-term device as a bridge to transplantation. Not surpris-
ingly, these patients pose a challenge for perioperative man-
agement and have severe abnormalities of hepatic, renal,
and pulmonary function.
Because of the changing nature of our patient population,
we believed that a reassessment of our screening scale was
appropriate. We now have the statistical power to develop a
score on the basis of multivariable analyses of data obtained
from a single institution. As suggested by Ivanov and col-
leagues,9 periodic recalibration of existing indices and re-
modeling of screening scores are necessary to ensure that
emerging risk factors are not inadvertently overlooked. The
advantage of a single-center study is the uniformity of
management practices, which removes this variable from
the outcome measures in multicenter analyses. However, an
admitted limitation is the potential lack of generalizability.
Therefore, the purpose of this report is to validate the
previous multicenter screening scale in a cohort of 130
consecutive patients receiving LVADs at our institution and
to determine whether there are emerging risk factors that
predict mortality in this challenging patient population.
Methods
Data Sources
All patients receiving the single-lead VE HeartMate LVAD were
observed by a dedicated nursing and medical staff. Pertinent peri-
operative clinical and demographic data were entered prospec-
tively into an institutional database. One hundred thirty consecu-
tive patients who received a device between June 1996 and March
2001 were included in this study. Details of surgical technique and
perioperative management have been published previously.1,10
Statistical Analysis
The SAS statistical software program version 8 for Windows (SAS
Institute, Cary, NC) was used for all statistical analyses. Categoric
data are expressed as their absolute or percentage frequency values
and were compared with 2or Fisher exact tests where appropriate.
Continuous data are expressed as the means  SD and were
compared by using the Student t test.
Model Derivation
The original summation score (Table 1) was derived from a
univariate analysis of 56 patients who received an LVAD as a
bridge to transplant at Columbia Presbyterian Hospital or The
Cleveland Clinic Foundation.5 We validated this index by using it
in our current data set, which contains no patient overlap with the
previous study. A stepwise logistic regression model was devel-
oped by using the 5 criteria specified in the original scoring
system, and the regression coefficients were then entered into an
equation to yield the predicted probability of mortality for each
patient. Patients were then grouped according to risk score (0-10),
TABLE 2. Perioperative demographic characteristics
Variable
Survivors
(n  97)
Nonsurvivors
(n  33) P value
Age (y) 49 14 52 14 .2
Female gender 17 (18) 8 (24) .4
Diagnosis .03
CAD 45 (46) 24 (73)
DCM 40 (41) 6 (18)
Other 12 (12) 3 (9)
Pre-LVAD 11 (11) 15 (45) .001
Pre-RVAD 3 (3) 7 (21) .001
Acute MI 25 (26) 15 (45) .03
Postcardiotomy 18 (19) 20 (61) .001
U/O  30 mL/hr 62 (64) 23 (70) .6
CVP  16 mm Hg 57 (59) 26 (79) .04
PT  16 s 48 (49) 24 (73) .02
Ventilated 38 (38) 28 (85) .001
CVVHD 29 (30) 24 (73) .001
Redo surgery 15 (15) 6 (18) .7
Numbers in parentheses refer to the corresponding percentage frequency.
CAD, Ischemic cardiomyopathy; DCM, dilated cardiomyopathy; Pre-LVAD,
temporary LVAD in situ at the time of HeartMate insertion; Pre-RVAD,
temporary RVAD in situ at the time of HeartMate insertion; MI, myocardial
infarction; U/O, urine output; CVP, central venous pressure; PT, prothrom-
bin time; CVVHD, perioperative need for continuous venovenous hemodi-
alysis.
TABLE 1. Previous risk factor summation score
Variable Relative risk P value Weighting
U/O 30 mL/h 3.9 .002 3
CVP 16 mm Hg 3.1 .02 2
Ventilated 2.9 .04 2
PT 16 s 2.4 .08 2
Redo surgery 1.7 .21 1
WBC 15,000/mm3 1.1 .86 0
Temperature 101.5°F 0.0 .56 0
U/O, Urine output; CVP, central venous pressure; PT, prothrombin time;
WBC, white blood cell count.
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and the mean probability of mortality was calculated for each
score.
The revised score was developed by reviewing all explanatory
variables with a univariate P value of less than .25 for operative
mortality after LVAD insertion. A revised score was then calcu-
lated by using the variables selected in a multivariable model, with
weights assigned according to their odds ratios (ORs), univariate
relative risks, or both (Table 2). Once again, a stepwise logistic
regression model was developed by using the 5 criteria specified in
the new summation score, and the probability of mortality was
calculated for each score as above.
The previous (old score) and revised (new score) summation
scales were then evaluated by plotting the predicted versus ob-
served mortalities at each risk score and calculating the slope and
y-intercept of the weighted linear regression line. A slope of 1 and
y-intercept of 0 indicates a perfect fit of predicted value to ob-
served outcomes and suggests an accurate summation score. The
different scoring scales were then compared by analyzing differ-
ences in slopes and intercepts by using analysis of covariance. In
addition, model discrimination was assessed by using the area
under the receiver operating characteristic (ROC) curve for each
score.9
Results
The demographic characteristics of the study population are
presented in Table 2, with a comparison of survivors and
nonsurvivors. Most of the previously identified risk factors
continue to be associated with higher mortality, with the
exception of renal insufficiency as defined by poor urine
output. Redo surgery (defined as remote sternotomy) no
longer predicts death. New univariate predictors of mortal-
ity include previous LVAD or right ventricular assist device
(RVAD) placement (bridge-to-bridge support), postcar-
diotomy shock, acute myocardial infarction, and ischemic
cardiomyopathy. A stepwise linear regression model iden-
tified a ventilated patient (OR, 5.7; 95% confidence interval,
1.8-17.5) and a previous LVAD (OR, 2.8; 95% confidence
interval, 1.0-7.9) as independent predictors of mortality
after device insertion. Table 3 shows the risk factors used to
devise the revised summation score and the relative risk
ratios for the variables excluded from the new score.
Figure 1 demonstrates the operative mortality associated
with both the old summation score and the new revised
score in the current patient population. Consistent with our
previous report, scores of greater than 5 in the old scale
were associated with significantly higher operative mortal-
ity (38% vs 13%, P  .001). In the new scale a score of
greater than 5 continued to be associated with higher mor-
tality (46% vs 12%, P  .001); however, the discrimination
between high and low risk was improved. Figure 2 com-
pares the discrimination between high and low risk on the
basis of scores of greater than 5 in both the old and new
scales. The sensitivity of a score of greater than 5 with the
new scale was similar to that of the old scale (73%, P .8).
However, the specificity of a score of less than 6 was 71%
by using the new scale and only 60% with the old scale
(P  .2).
Figure 3 displays the ROC curves associated with both
the old and new scoring systems. Both scores demonstrated
adequate statistical precision to predict operative mortality,
although the new scale was associated with a slightly higher
area under the ROC curve. Figure 4 plots the observed
versus predicted mortality for all 130 patients by using both
the old scale (upper panel) and the new scale (lower panel),
along with a linear regression line constructed for each
scale. The old scale yielded excellent correlation between
predicted and observed values (r  0.88); however, the
slope of the relation was significantly different from 1 ( 
1.46  0.05, P  .01), and the y-intercept was significantly
different from 0 (c  11.7  1.4, P  .001), suggesting
that the old scale significantly underestimated actual mor-
tality in higher-risk patients. In contrast, the new scale
demonstrated a similar correlation (r  0.87), with a slope
closer to 1 (  1.00  0.04, P  .8) and a y-intercept not
different from 0 (c  0.004  1.3, P  .9).
Discussion
Chronic congestive heart failure is the only cardiovascular
diagnosis increasing in prevalence.11 As the use of mechan-
ical assistance to support this population increases, the
indications for device implantation need to be clarified.
Although individual patients will undoubtedly benefit from
this technology, the cost-benefit ratio of this therapy might
not justify device insertion in all potential recipients.12 The
increased interest in public reporting of surgical results has
led to the development of many risk indices for mortality
after isolated coronary bypass surgery.9,13-15 Unfortunately,
the relatively small clinical experience in single centers has
made derivation of similar risk indices for LVAD insertion
difficult.
To provide a common denominator with which to begin
TABLE 3. Revised risk factor summation score
Variable Sample size Relative risk P value Weighting
Ventilated 66 5.3 .0001 4
Postcardiotomy 38 3.3 .0001 2
Pre-LVAD 26 3.3 .0001 2
CVP 16 mm Hg 83 2.1 .04 1
PT 16 s 72 2.1 .02 1
Variables excluded Sample size Relative risk Univariate P value
Pre-RVAD 10 3.2 .0007
Diagnosis CAD 69 2.0 .03
Acute MI 40 1.7 .03
U/O 30 mL/h 85 1.2 .55
Redo surgery 21 1.2 .71
CVP, Central venous pressure; PT, prothrombin time; CAD, ischemic car-
diomyopathy; MI, myocardial infarction; U/O, urine output.
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discussions with referring physicians, we devised a risk
factor summation scale that successfully predicted operative
mortality in HeartMate recipients.5 To achieve the neces-
sary statistical power, we combined the clinical experience
of Columbia Presbyterian Hospital and The Cleveland
Clinic Foundation to analyze a total of 56 LVAD recipients.
The summation score derived from this earlier study per-
formed satisfactorily in the present analysis, which included
a single center’s experience with 130 consecutive patients.
There are advantages and disadvantages of deriving a
risk index from a single center’s experience. The major
advantages include uniformity of care and relevance to that
center’s patient population. The disadvantage lies in its
potential lack of generalizability to larger patient popula-
tions and to centers with different management algorithms.
Regardless of the data sources, it is useful to periodically
update and remodel existing risk indices to detect emerging
hazards and to assess the relative effect of known risk
factors.
The purpose of the original scale was to provide LVAD
teams with a quick screening tool to determine operative
risk in potential device recipients. At our center, we found
this tool to be extremely useful when initiating dialogues
with referring physicians from “spoke” centers (ie, referral
centers without the capability of providing long-term me-
chanical assistance or transplantation).7 However, our clin-
ical observation that the increasing proportion of patients
presenting with postcardiotomy shock faced increased op-
erative risk prompted us to reexamine our risk factor sum-
mation score. Our analysis provided some expected results
but also revealed surprising trends in previously important
variables.
Effect of Postcardiotomy Shock
The 3 most important variables in the new scoring scale all
reflect the high-risk nature of a patient with postcardiotomy
cardiogenic shock. Most series report a survival to hospital
discharge of only 20% to 40%.7,8,16,17 A ventilated patient
presenting with a temporary LVAD in situ has already
achieved a score of 8 (predicted mortality of 37%). The fact
that mechanical ventilation emerged as the most important
multivariable predictor of death (OR, 5.7) reflects the un-
derlying status of a patient who is deemed to require endo-
tracheal intubation. Although measurements of inspired ox-
ygen concentration, oxygen saturation, or Po2 might provide
valuable clinical information, the deliberate act of endotra-
cheal intubation is a binomial criterion with high discrimi-
natory powers. As a result of these considerations, mechan-
ical ventilation earned 4 points on the revised scoring scale
Figure 1. Relationship between operative mortality and risk factor summation score. Both the old score and the
new score successfully predicted risk after LVAD insertion. In both scales a score of greater than 5 is associated
with high mortality.
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and represents the single most important risk factor for
mortality after LVAD insertion.
The technical aspects of redo surgery, including the
increased risk of bleeding and myocardial injury during
sternal reentry, are no longer statistically significant, with a
relative risk of only 1.2 compared with 1.7 in the old scale.
Postcardiotomy shock conferred a relative risk of 3.3 and
replaced redo surgery as a variable in the new scale. Most
patients with a temporary LVAD suffered from postcar-
diotomy shock. All but 4 patients (1 device failure, 1 epi-
Figure 2. Discrimination between high and low risk (score >5) for mortality after LVAD insertion. Although both
scales successfully predicted risk, the new scale improved discrimination.
Figure 3. ROC curves for the old (left) and new (right) risk factor summation scores. Both scores display adequate
statistical accuracy, with slightly better accuracy in the new score (area under the ROC curve, c  0.77 vs 0.73).
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sode of cardiogenic shock after acute myocardial infarction,
and 2 episodes of acute myocarditis) presented with a de-
vice after a failed cardiac surgical procedure. The presence
of a temporary device is an indicator of the degree of
hemodynamic instability and is an important risk factor in
the new scale, with a relative risk of 3.3.
Although a previous RVAD emerged as a significant
univariate predictor of mortality (relative risk, 3.2; P 
.007), the small sample size (n  10) precluded meaningful
analysis. In addition, all 10 patients presented with both a
left and right-sided device. Therefore RVAD in situ was
excluded as a variable in the new screening scale.
When postcardiotomy shock and previous LVAD inser-
tion were presented to the multivariable model, only previ-
ous LVAD insertion emerged as an independent predictor of
mortality (OR, 2.83). However, because of the challenges of
LVAD insertion in a patient with recent cardiac surgery, we
elected to award 2 risk points for postcardiotomy shock in
addition to the 2 risk points awarded for a previous LVAD
in situ.
Acute myocardial infarction and a diagnosis of ischemic
cardiomyopathy were weakly interrelated univariate predic-
tors. Because of the significant overlap between these 2
variables and their failure to emerge as independent predic-
tors in the multivariable analysis, we elected to exclude
them in the revised screening scale.
Effect of End-Organ Function
The most striking finding in the present analysis is the lack
of effect of preoperative renal insufficiency. Although mea-
surements of serum creatinine might provide additional
information, it is insensitive and lags behind changes in
renal function. In addition, interpretation of isolated values
is difficult because the context might involve recovery from
a remote injury or worsening function from prolonged
shock. We have previously found that urine output in the
immediate preoperative hours is a sensitive indicator of
renal function and was the most important predictor of
mortality in the old screening score. However, a more
aggressive approach to oliguria and the earlier institution of
Figure 4. The relation between observed and predicted mortality by using the old (top) and new (bottom) scales.
The correlation between observed and predicted values was excellent in the new score (r  0.87), with the slope
of the linear regression line close to 1 and a y-intercept close to 0, suggesting accurate predictive ability. In the
old score correlation between observed and predicted values was excellent (r  0.88), but the slope of the linear
regression line was significantly greater than 1 (P < .01), and the y-intercept was significantly less than 0 (P <
.001). Thus the score overpredicted mortality in patients at low risk (predicted mortality of <30%) and underpre-
dicted mortality in patients with predicted mortalities of greater than 30%.
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ultrafiltration or hemodialysis has attenuated the effect of
this risk factor. As a result, immediate preoperative urine
output is no longer represented on the risk factor summation
score. However, it is clear from Table 2 that the develop-
ment of postoperative renal failure is still a strong predictor
of outcome after LVAD insertion. Therefore continued at-
tention to the perioperative management of renal function is
imperative, despite the fact that it is no longer a preoperative
predictor of mortality.
Similarly, the effect of hepatic and right-heart failure has
attenuated with time. In the old scale the relative risk of a
prolonged prothrombin time (16 seconds) was 2.4 com-
pared with 2.1 in the new scale. The relative risk of an
increased central venous pressure (16 mm Hg), a marker
of poor right heart function used to be 3.1 and in the present
study has fallen to 2.1. Again, the aggressive treatment of
volume overload has decreased the relative effect of both of
these risk factors. Earlier institution of continuous veno-
venous hemodialysis leads to less hepatic congestion and
improved right heart function. Decreasing hepatic conges-
tion improves the synthetic function of the liver, thereby
improving coagulation and decreasing the need for blood
product transfusions. The inflammatory cytokine response
to heterologous blood transfusion is associated with wors-
ening right-heart function.18,19 Because both increased cen-
tral venous pressure and prothrombin time were associated
with increased risk by means of univariate analysis, they
were each awarded 1 point in the revised scoring scale.
Comparison of Screening Scores
The results of our analysis validate the previous summation
score, which was derived from a different cohort of patients
from 2 separate institutions. The old score satisfactorily
predicted survival, with a threshold of 5 discriminating
high-risk patients (38% vs 13%, P  .001). The new score
provided improved discrimination, with a threshold of 5
representing a 46% risk compared with the 12% risk in
patients with scores of less than 5 (P  .001). The area
under the ROC curves were similar, with slightly higher
accuracy in the new scale (0.77 vs 0.73). The relationship
between observed and predicted values was greatly im-
proved in the new scale. The old scale overestimated mor-
tality in patients with predicted survival of greater than 70%
and underestimated mortality in high-risk patients with pre-
dicted survivals of less than 70%. In contrast, there was
excellent correlation between observed and predicted out-
comes when the revised scoring scale was used (slope 
1.00, r  0.87).
Summary
As the effect of mechanical circulatory assistance for the
treatment of acute and chronic heart failure increases, a
greater proportion of patients will present for device con-
sideration at high risk for perioperative mortality. Identifi-
cation of the preoperative variables, which accurately pre-
dict risk, is important for both resource use and for revising
management strategies for these challenging patients. A
dramatic example of this concept is illustrated in the present
report, which documents the changing effect of preoperative
renal status on perioperative mortality. Identification of
poor urine output in our previous analysis led us to adopt a
more aggressive approach to the treatment of impending
renal failure. As a result of this paradigm shift, we have
improved our perioperative management of overall volume
status, and thus poor urine output, increased central venous
pressure, and prolonged prothrombin time no longer in-
crease operative risk significantly.
The present analysis suggests that the predominant pre-
dictor of risk in contemporary patients receiving LVADs is
the preoperative requirement for mechanical ventilation.
New strategies aimed at improving pulmonary function
might help to mitigate the effect of this variable and im-
prove the clinical results of mechanical circulatory support
in an increasingly high-risk patient population. The current
study is based on a single center’s experience with only one
of the available long-term implantable devices. A prospec-
tive multicenter experience is needed to validate the con-
clusions of this report.
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